Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Anal Cancer, Colostomy, and Ileostomy.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Endoscopy.

Akila Viswanathan, M.D., M.P.H., is the director for the Department of Radiation Oncology and Molecular Radiation Sciences, and a professor of radiation oncology, gynecology/obstetrics and oncology for Johns Hopkins University School of Medicine. Dr. Viswanathan leads the department emphasizing excellence in clinical care, research and education. She has expertise with gynecologic cancers and their treatment, including cervical and uterine cancers and image-guided brachytherapy. She has developed numerous clinical innovations and initiated several system-wide integration efforts at all sites, including Green Spring Station, Bayview, Johns Hopkins Hospital, Suburban's Rockledge site, and Sibley Memorial Hospital for the Johns Hopkins Department of Radiation Oncology. Dr. Viswanathan earned her undergraduate degree at Harvard University, her medical degree at the University of Pittsburgh School of Medicine, followed by her Masters in Public Health and Masters in Epidemiology at the Harvard School of Public Health. She completed a residency in radiation oncology at the Joint Center for Radiation Therapy at Harvard Medical School, where she served as chief resident. She has had research grant funding through the National Cancer Institute K07, R21 and R01 programs to support efforts in gynecologic cancers, specifically looking at the identification of gynecologic tumors at the time of brachytherapy under magnetic resonance imaging. The research team has developed several novel clinical innovations. Dr. Viswanathan has been named one of America's Top Doctors by Newsweek, Who’s who in America, and a Super Doctor by the Washington Post magazine. Dr. Viswanathan served as President and Chair of the Board of the American Brachytherapy Society; Chair of Education Committee for American Society for Radiation Oncology; and, on the Gynecologic Cancer Steering Committee and the uterine cancer task force for the National Cancer Institute. Dr. Akila Viswanathan has published more than 200 articles and chapters, and lectures nationally and internationally. She is the Editor-in-Chief for Seminars in Radiation Oncology. She is on the editorial board of Gynecologic Oncology and Brachytherapy, and is an editor of several textbooks including Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management, Radiation Therapy Techniques for Gynecologic Cancers, and Gunderson and Tepper's Clinical Radiation Oncology. Make A Gift. Dr. Viswanathan is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Vaginal Cancer, Cervical Cancer, Vulvar Cancer, Vulvectomy, and Cordotomy.

Dr. Rebecca Stone is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. Dr. Stone is a highly skilled surgeon with expertise in laparoscopic and robotic surgery for gynecologic tumors. She also serves as director of the Gynecology Enhanced Recovery after Surgery initiative, an innovative, multidisciplinary program that improves recovery and healing time after major abdominal surgery, as well as minimizes health care costs for patients. Dr. Stone received her undergraduate degree in biology from the University of Virginia. She earned her medical degree from the University of Virginia School of Medicine, where she subsequently completed her residency in obstetrics and gynecology. Dr. Stone performed a four-year gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. She also earned a master’s degree in cancer biology from the University of Texas in 2010. Prior to joining Johns Hopkins, Dr. Stone was an assistant professor at the University of Arkansas for Medical Sciences, where she was one of five gynecologic oncologists serving the entire state. Dr. Stone is internationally recognized for her research pertaining to early diagnosis and treatment of ovarian cancer. She is widely published in the field of gynecologic oncology, with first-author papers in the New England Journal of Medicine and Lancet Oncology, as well as over 40 co-authored manuscripts in peer-reviewed medical journals. She was honored with an award for one of the most influential papers published in the field of obstetrics and gynecology in 2012 and with an Ovarian Cancer Research Fund Grant for “Unplugging Ovarian Cancer from the Power of Platelets.” Dr. Stone strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life. She enjoys working with community providers so that patients are comforted by receiving care close to home. Dr. Stone is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Dr. Robert Liddell is an Assistant Professor of Radiology and Surgery and Division Chief of Interventional Radiology at the Johns Hopkins School of Medicine. His specialty is interventional radiology, with an expertise in interventional oncology and vascular and interventional radiology. Dr. Liddell received his MBBCh at the Royal College of Surgeons in Ireland. He completed his residency at Johns Hopkins University School of Medicine in Diagnostic Radiology and his fellowship in Interventional Radiology. Videos Interventional Radiology. Dr. Liddell is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bile Duct Obstruction, Ascites, Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

Dr. Johnson is a genitourinary medical oncologist who specializes in treating patients with bladder cancer and upper tract urothelial carcinoma. He is a member of the Greenberg Bladder Cancer Institute. He obtained his M.D. and Ph.D. degrees from the Medical College of Georgia, where he completed his residency in Internal Medicine. He then completed his medical oncology fellowship and did additional postdoctoral research at Johns Hopkins before joining the faculty. He has an active laboratory which focuses on optimizing bladder cancer preclinical models, studying mechanisms of bladder cancer progression, elucidating biomarkers that correlate with bladder cancer survival and response to treatment, and testing immunotherapies in bladder cancer preclinical models. His research has been funded by an ASCO Young Investigator Award, an AACR-BMS Fellowship for Young Investigators in Translational Immuno-oncology, a Harry J. Lloyd Charitable Trust Career Development Award, a Bladder Cancer Advocacy Network Young Investigator Award, and a Department of Defense Career Development Award. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, and Urothelial Cancer.

"Dr. Katarzyna J. Macura is a professor in the Johns Hopkins Medicine department of radiology and radiological science, a professor of oncology and urology at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Precision Medicine Center of Excellence for Prostate Cancer. She is a radiologist consultant for the Prostate Cancer Multidisciplinary Clinic at The Johns Hopkins Hospital in Baltimore, MD. Dr. Macura established a clinical and research prostate imaging program with a focus on magnetic resonance imaging (MRI). Dr. Macura has expertise in cross-sectional body imaging, MRI and prostate cancer, and image-guided biopsies. Dr. Macura earned her medical degree from the Medical University of Lodz in Poland. She completed a residency in diagnostic radiology at the Medical College of Georgia and a fellowship in cross-sectional body imaging at Johns Hopkins University. Prior to arrival at Hopkins in 2000, Dr. Macura completed post-doctoral research in Artificial Intelligence at the University of Georgia in Athens, GA. With a PhD degree in Medical Informatics, she had pioneered early applications of Artificial Intelligence for medical decision support, a domain that is now rapidly expanding owing to the advancement of computer technologies and recent recognition that decision support augments appropriate utilization of medical technologies, provides second opinion systems for improved diagnostics and management, and allows optimization of medical care delivery with the assessment of quality and safety. Dr. Macura is a certified knowledge engineer. Dr. Macura is a member of several national and international radiology organizations. She served as president of the Maryland Radiological Society, the Maryland Chapter of the American College of Radiology (ACR), between 2013 and 2015, as well as president of the American Association for Women in Radiology (AAWR) in 2005. She was a Chancellor on the ACR Board of Chancellors, serving as the Inaugural Chair of the ACR Commission for Women and Diversity, between 2013 and 2019. She served as Vice-President of the ACR 2019-2020. She was named the Outstanding Teacher of the Year by Hopkins Radiology Residents in 2005 and 2021, and received the Resident Mentoring Awards in 2018 and 2024. Dr. Macura was also named the Honored Educator by the Radiological Society of North America in 2012 and 2014. In 2016, she received the ""Diamond"" Jim Brady Urology Residents teaching award and the AAWR Marie Sklodowska-Curie award. In 2022, she received the Gold Medal from the American College of Radiology. Dr. Macura is a Fellow of the American College of Radiology (FACR), the Society for Advanced Body Imaging (FSABI), and the American Association for Women in Radiology (FAAWR).". Dr. Macura is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Muscle Invasive Bladder Cancer, Fibrolamellar Carcinoma, Renal Cell Carcinoma (RCC), Prostatectomy, and Penectomy.

Dr. Cheng Ting Lin is an associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine. His expertise is in diagnostic radiology with particular focus on chest and cardiac imaging. Dr. Cheng Ting Lin received his undergraduate degree from Boston University. He graduated from State University of New York at Stony Brook, where he also completed a radiology residency training program. Dr. Lin completed fellowship training in cardiothoracic imaging at University of Maryland Medical Center. His research interest includes lung cancer screening and diagnosis, chronic obstructive pulmonary disease, Interstitial lung disease, pulmonary embolism, and coronary artery disease. Dr. Lin is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Lung Nodules, Interstitial Lung Disease, Pulmonary Arteriovenous Fistula, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Dr. Andrew J. Cohen is an Associate Professor of Urology at Johns Hopkins. He serves as the Division Director of Benign Urology and Director of Advanced Practice Providers at the Johns Hopkins Brady Urological Institute. He has a robust clinical practice focusing on complex genitourinary reconstruction. In particular, he has interest in the management of erectile dysfunction, urinary incontinence, stricture diseases of the urinary system, peyronie's disease, genital skin conditions, buried penis, urinary diversion, and other benign urologic conditions. He has extensive experience in robotic surgery. He also focuses on issues pertinent to cancer survivorship in men. He is well equipped to perform novel minimally invasive procedures such as endoscopic urethroplasty and robotic buccal ureteroplasty. He has an extensive research portfolio, with particular concentration in outcomes and safety research. Dr. Cohen received dual B.S. degrees summa cum laude from the University of Florida in Chemistry and Chemical Engineering, followed by an MD from the University of Chicago where he was inducted into the Alpha Omega Alpha Honor Society. His urologic training was pursued at the University of Chicago. Furthermore, he completed a fellowship in Genitourinary Reconstruction and Trauma at the University of California, San Francisco. Among many honors, he was invited to join the Trauma and Urologic Reconstructive Network of Surgeons in 2025. He was a also a recipient of the 'Rising Star' Award from the Society of Genitouinary Reconstructive Surgeons in 2025. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Urethral Stricture, Hydronephrosis, Obstructive Uropathy, Prostatectomy, and Lithotripsy.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Alan Kusakabe is a Urologist in Baltimore, Maryland. Dr. Kusakabe is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Obstructive Uropathy, Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, Vasectomy, and Reconstructive Urology Surgery. Dr. Kusakabe is currently accepting new patients.

Michael Phelan is a Urologist and a General Surgeon in Baltimore, Maryland. Dr. Phelan is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery. Dr. Phelan is currently accepting new patients.